{"product_id":"a-bcg-matrix","title":"(A) Agilent Technologies, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVisual. Strategic. Downloadable.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Agilent Technologies, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report instantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLC-MS systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgilent Technologies, Inc.’s LC-MS systems fit a Star in its BCG Matrix: they serve fast-growing biopharma, proteomics, and regulated testing demand, while a large installed base drives repeat method-development and service pull-through. In FY2025, Agilent generated about $6.5 billion in revenue, and LC-MS stays central to its higher-margin analytical workflow mix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eICP-MS instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eICP-MS is a Star for Agilent Technologies, Inc.: it serves elemental impurities, PFAS, environmental, and semiconductor testing, where demand stays strong as EPA PFAS limits tighten to 4 ppt for PFOA and PFOS and chip fabs need ultra-trace contamination control. Agilent’s FY2025 revenue was about $6.9 billion, backing this high-value platform. It is a major supplier in a niche with high margins and a sticky installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGC-MS workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGC-MS workflows are a Star for Company Name because they serve food, environmental, forensics, and industrial QA labs that need trace-level and compliance testing. Agilent Technologies, Inc. reported FY2025 revenue above $6 billion, and its broad chromatography plus mass spectrometry stack helps it win bundled sales and keep adoption high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCell analysis solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCell analysis is a Star for Agilent Technologies, Inc. because demand is rising in immunology, cell therapy, and translational research. Agilent’s flow cytometers, real-time cell analyzers, and imaging tools fit higher-end workflows, so they can support premium pricing and recurring consumable pull-through. This space should keep growing as labs need faster, more precise live-cell data.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong demand from cell therapy\u003c\/li\u003e\n\u003cli\u003eSupports high-value workflows\u003c\/li\u003e\n\u003cli\u003eBuilds on Agilent’s life science base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma analytical workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharma analytical workflows are a Star because R\u0026amp;D and QC need linked steps, not stand-alone tools. Agilent spans separation, detection, sample prep, and software, which fits regulated labs; Agilent reported FY2025 revenue of about $6.5 billion, and this workflow-led demand helps defend that base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-step use beats single-instrument selling.\u003c\/li\u003e\n\u003cli\u003eIntegrated lab fits support sticky regulated demand.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgilent’s Star Platforms Power Growth, Margin Protection, and Lab Upgrades\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgilent Technologies, Inc. Stars include LC-MS, ICP-MS, GC-MS, cell analysis, and biopharma workflows: these are high-growth, high-value niches with sticky installed bases and strong pull-through. FY2025 revenue was about $6.5 billion, and these platforms help protect mix and margins as labs keep upgrading.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLC-MS\u003c\/td\u003e\n\u003ctd\u003eBiopharma and proteomics demand\u003c\/td\u003e\n\u003ctd\u003eLarge workflow pull-through\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eICP-MS\u003c\/td\u003e\n\u003ctd\u003ePFAS and trace metals testing\u003c\/td\u003e\n\u003ctd\u003eHigh-value regulated use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGC-MS\u003c\/td\u003e\n\u003ctd\u003eCompliance and QA labs\u003c\/td\u003e\n\u003ctd\u003eBroad installed base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAgilent’s BCG Matrix shows which units to invest in, hold, or divest across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Agilent BCG Matrix clarifying portfolio priorities and easing strategic decisions\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eGives a credible source trail for Agilent Technologies, Inc., helping decision-makers verify assumptions fast and trust the analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLC systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLC systems fit Cash Cows because liquid chromatography is a mature lab market with a large installed base and steady replacement demand. Agilent Technologies, Inc. keeps revenue stable through method continuity, service, and consumables, while its Life Sciences and Applied Markets unit still drives most of the company’s ~$6.5 billion fiscal 2025 revenue base. That makes Agilent a leading routine-lab vendor with predictable, repeat repeat sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGC systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAgilent Technologies, Inc. reported FY2025 revenue of about $6.98 billion, and GC systems stayed a mature line inside its lab-testing portfolio. Gas chromatography is still a core QC tool in pharma, food, and environmental labs, so the large installed base keeps consumables and service demand steady. Growth is slower than omics tools, but that installed base makes GC a dependable cash generator.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eColumns and sample prep consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eColumns and sample prep consumables are a cash cow because they get replaced again and again as Agilent’s installed base keeps running. Agilent reported $6.51 billion in FY2024 revenue, and this recurring stream usually carries higher margins than hardware. CrossLab strengthens that annuity-like demand by tying consumables, services, and support to instrument use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCrossLab service contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCrossLab service contracts fit the Cash Cows box because they are recurring, tied to instruments already in customer labs, and less dependent on new market growth. Agilent Technologies, Inc. reported FY2025 revenue near $6.8 billion, and this installed-base model keeps cash flow steady through service, startup support, compliance, and asset management.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring revenue from the installed base\u003c\/li\u003e\n\u003cli\u003eLow growth need, steady cash generation\u003c\/li\u003e\n\u003cli\u003eSupports labs after instrument sale\u003c\/li\u003e\n\u003cli\u003eBoosts retention and lifetime value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRoutine lab software and maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoutine lab software and maintenance is a classic Cash Cow for Agilent Technologies, Inc. Installed-base tools and service contracts keep labs running, so customers pay for upgrades, validation, and uptime instead of frequent new buys. That creates steady, low-growth cash with high renewal value. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring support beats new unit sales\u003c\/li\u003e\n\u003cli\u003eUptime and validation drive renewals\u003c\/li\u003e\n\u003cli\u003eStable cash, low capital need\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAgilent Technologies, Inc. also benefits from a large installed base across analytical labs, which makes this stream sticky and defensive.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgilent’s Cash Cows: Recurring Lab Revenue Powers FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAgilent Technologies, Inc.’s Cash Cows are its installed-base businesses: LC and GC systems, columns, sample prep, CrossLab service, and routine software support. FY2025 revenue was about $6.98 billion, and these lines stay strong because labs replace consumables and renew service, not just buy new tools.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eLC, GC, CrossLab\u003c\/td\u003e\n\u003ctd\u003eRecurring installs and renewals\u003c\/td\u003e\n\u003ctd\u003eAbout $6.98B revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAgilent Technologies, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the same Agilent Technologies, Inc. BCG Matrix document you’ll receive after purchase. No sample pages or demo content—just the full, ready-to-use report. Download the exact file instantly and use it for analysis, presentations, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAtomic absorption (AA)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAtomic absorption is a legacy elemental analysis tool, and it fits the Dogs bucket because adoption has lagged ICP-MS and ICP-OES. It still has a place in some labs for routine single-element work, but growth is thin and replacement risk is high. Agilent’s FY2025 spending and product focus remain centered on newer, higher-throughput platforms, not AA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMP-AES\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMP-AES is a niche elemental-analysis tool, so it fits Agilent Technologies, Inc. as a Dogs\/low-share, low-growth asset in the BCG Matrix. It trails ICP-based methods, which dominate the broader inorganic analysis market and keep most growth in higher-end platforms. That makes MP-AES less central to Agilent Technologies, Inc.’s core growth story and more of a maintenance product than a scale driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy DNA microarrays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy DNA microarrays sit in the Dogs quadrant for Agilent Technologies, Inc. because the platform is mature and has been displaced by next-generation sequencing. Agilent’s FY2025 base is now centered on higher-growth genomics tools, while microarrays face structurally weaker demand as labs shift to sequencing-first workflows. That leaves this franchise low-growth, lower-priority, and mainly a cash harvest play.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eH\u0026amp;E and older ISH staining lines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eH\u0026amp;E and older ISH staining lines sit in a mature, crowded pathology market, so volume grows slowly and pricing power is limited. Agilent’s FY2025 mix still favors faster tools like molecular diagnostics and sequencing, while legacy stains face stronger competition from large, established lab suppliers. This makes the unit a classic Dog in the BCG Matrix: low growth, modest share, and weak differentiation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMature market, slower growth\u003c\/li\u003e\n\u003cli\u003eLimited tech edge versus newer assays\u003c\/li\u003e\n\u003cli\u003eLow BCG Matrix attractiveness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core vacuum and general measurement products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgilent Technologies, Inc.’s non-core vacuum and general measurement products sit outside its chromatography and genomics engines, so they usually act more like cash-drain or maintenance lines than growth drivers. Agilent reported FY2025 revenue of about $6.7 billion, but it does not break out these smaller products separately, which itself signals their limited strategic weight.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePeripheral, not core\u003c\/li\u003e\n\u003cli\u003eLow growth, more commoditized\u003c\/li\u003e\n\u003cli\u003eNot a main expansion engine\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgilent’s Dog Lines Are Legacy Cash Harbors, Not Growth Engines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs in Agilent Technologies, Inc. stay tied to legacy, low-growth lines like atomic absorption, MP-AES, DNA microarrays, and older H\u0026amp;E\/ISH stains. They face displacement from ICP-based tools, next-gen sequencing, and newer pathology workflows, so FY2025 capital and product focus stayed on higher-growth platforms. These lines look more like cash-harvest assets than growth engines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog line\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG view\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtomic absorption\u003c\/td\u003e\n\u003ctd\u003eLegacy, lagging adoption\u003c\/td\u003e\n\u003ctd\u003eLow growth, low share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMP-AES\u003c\/td\u003e\n\u003ctd\u003eNiche vs ICP methods\u003c\/td\u003e\n\u003ctd\u003eMaintenance asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDNA microarrays\u003c\/td\u003e\n\u003ctd\u003eSequencing displacement\u003c\/td\u003e\n\u003ctd\u003eCash harvest\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eH\u0026amp;E\/older ISH\u003c\/td\u003e\n\u003ctd\u003eMature pathology market\u003c\/td\u003e\n\u003ctd\u003eWeak differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTarget enrichment for NGS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTarget enrichment for NGS sits in a growing market, but share is still hard to win. Agilent Technologies, Inc. plays here through enrichment workflows and software, while the broader NGS market was about $15.5 billion in 2025 and is still expanding at high single digits. The category is a question mark, so Agilent likely needs more investment to scale share against fierce rivals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLiquid-based pharmacodiagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLiquid-based pharmacodiagnostics fits the Question Marks box: it is a developing diagnostics area with clear upside, but current market share is still likely small. Agilent Technologies, Inc. has treated adjacent diagnostics and lab workflow tools as growth bets, even though its fiscal 2024 revenue was $6.51 billion, showing the group still has scale but this niche is early-stage. If adoption rises, it can grow fast; if not, it may stay a low-share bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab automation and robotics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLab automation and robotics look like a Question Mark for Agilent Technologies, Inc.: demand is rising in life sciences and applied labs, but the field is crowded with specialists. Agilent generated $6.51 billion in fiscal 2024 revenue, yet this niche still needs more spend to win share. Stronger products, service, and software will decide if it becomes a Star or stays a small bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSaaS lab informatics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSaaS lab informatics fits BCG Question Mark for Agilent Technologies, Inc.: cloud lab software is growing fast as labs digitize workflows, but competition is still crowded and Agilent does not show clear share dominance. Agilent Technologies, Inc. has broad data management and analytics tools, yet this line looks like a build-or-buy bet, not a cash cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, unclear share\u003c\/li\u003e\n\u003cli\u003eStrong digitization tailwind\u003c\/li\u003e\n\u003cli\u003eCompetitive market pressure\u003c\/li\u003e\n\u003cli\u003eNeeds scale to win\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvanced imaging systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced imaging systems are a Question Mark for Agilent Technologies, Inc. because cell biology and translational research demand is rising, but the field is crowded with Leica, Zeiss, Nikon, and Thermo Fisher. FY2025 peer spending stayed heavy on R\u0026amp;D, so the upside is real, but Agilent still has to win share, not just ride demand. Growth can be strong, yet market position remains the key test.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowing demand, but tough peer set\u003c\/li\u003e\n\u003cli\u003eShare gains matter more than category growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAgilent’s Question Marks: Big 2025 Markets, But Share Still Up for Grabs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks need capital but still lack clear share. In Agilent Technologies, Inc., NGS target enrichment, lab automation, SaaS informatics, and advanced imaging sit in 2025 growth markets, yet rivals still control much of the share. The 2025 NGS market was about $15.5 billion, so the upside is real, but Agilent must spend to win.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNGS enrichment\u003c\/td\u003e\n\u003ctd\u003e$15.5B market\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation\u003c\/td\u003e\n\u003ctd\u003eHigh growth, crowded\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab SaaS\u003c\/td\u003e\n\u003ctd\u003eFast digitization\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191732445449,"sku":"a-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/a-bcg-matrix.webp?v=1783678412","url":"https:\/\/dcfanalyst.com\/products\/a-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}